TABLE 2.

In vivo efficacy of auranofin in animal models.

Mouse models	Route of administration	Bacterial strains	Result of the experiment	References
Skin infection model	Topical (petroleum gel as vehicle)	S. aureus (MRSA USA300)	Reduction of MRSA CFU (3.64 ± 0.14 log10) Reduction in inflammatory cytokines tested (IL-6, IL-1β, TNFα and MCP-1)	Thangamani et al., 2016b
Murine systemic infection	Peritoneal	S. aureus (MRSA strain Sanger 252)	Survival of mice after for 7 d after treatment	Harbut et al., 2015
Peritonitis–sepsis infection model	Oral	S. pneumoniae serotype 23F strain; serotype 8 strain (strain 3498)	Reduced mortality and 50% of mice survived Reduction in bacterial load within 24h	Aguinagalde et al., 2015
Intramuscular infection	Subcutaneous	S. aureus (MRSA 132)	Reduction of bacterial load within 24h	Aguinagalde et al., 2015
Mesh associated biofilm infection	Intraperitoneal	S. aureus (MRSA 132)	Decrease in bacterial load attached to the mesh	Aguinagalde et al., 2015
C. difficile infection model	Intraperitoneal	C. difficile	Protected 100% of mice at lowest concentration of drug (0.25 mg/Kg) from C. difficile infection	Abutaleb and Seleem, 2020
Infected pressure ulcer wound model in obese mice	Topical	S. aureus MRSA	8-log10 reduction in MRSA	Mohammad et al., 2020